Yet another field of clinically applicable dialogue focuses on the analysis of bevacizumab mixture cure with varied cytotoxic brokers. (For qualified therapy coupled with cytotoxic agents in the adjuvant location, begin to see the respective part.)g., PARP inhibitor) being a consequence of data on using PARP inhibitors in BRCA1/2 mutation carriers